- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05169567
Abemaciclib (LY2835219) Plus Fulvestrant verrattuna Placebo Plus Fulvestrantiin aiemmin hoidetussa rintasyövässä (postMONARCH)
postMONARCH: satunnaistettu, kaksoissokkoutettu, lumekontrolloitu, vaiheen 3 tutkimus Abemaciclib Plus Fulvestrantin ja Placebo Plus Fulvestrantin tehokkuuden vertaamiseksi osallistujilla, joilla on HR+, HER2-, pitkälle edennyt tai metastaattinen rintasyöpä, jotka ovat edistyneet CDK4- ja Endocrinhitorilla Terapia
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 3
Laajennettu käyttöoikeus
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
San Juan, Argentiina, 5400
- CER San Juan
-
-
Buenos Air
-
Buenos Aires, Buenos Air, Argentiina, C1426ABP
- Fundación Respirar
-
Ciudad Autónoma de Buenos Aire, Buenos Air, Argentiina, C1027AAP
- Centro de Investigaciones Metabólicas (CINME)
-
-
Buenos Aires F.D.
-
CABA, Buenos Aires F.D., Argentiina, 1125
- Fundación Cenit Para La Investigación En Neurociencias
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentiina, 5800
- Instituto Médico Río Cuarto
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentiina, 4000
- Centro Medico San Roque
-
-
-
-
-
Namur, Belgia, 5000
- CHU UCL Namur/Site Sainte Elisabeth
-
-
Antwerpen
-
Brasschaat, Antwerpen, Belgia, 2930
- Algemeen Ziekenhuis klina
-
-
Limburg
-
Hasselt, Limburg, Belgia, 3500
- Jessa Ziekenhuis
-
-
-
-
-
Badajoz, Espanja, 06006
- Hospital Infanta Cristina
-
Madrid, Espanja, 28009
- Hospital General Universitario Gregorio Marañon
-
Toledo, Espanja, 45007
- Hospital Universitario de Toledo
-
-
A Coruña [La Coruña]
-
A Coruña, A Coruña [La Coruña], Espanja, 15006
- CHUAC-Hospital Teresa Herrera
-
-
Balears [Baleares]
-
Palma, Balears [Baleares], Espanja, 07120
- Hospital Universitari Son Espases
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], Espanja, 08003
- Parc de Salut Mar - Hospital del Mar
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Espanja, 08036
- Hospital Clínic de Barcelona
-
-
Murcia, Región de
-
El Palmar, Murcia, Región de, Espanja, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Málaga
-
Málaga, Málaga, Espanja, 29011
- H.R.U Málaga - Hospital Materno-infantil
-
-
Navarre
-
Pamplona, Navarre, Espanja, 31009
- Complejo Hospitalario de Navarra
-
-
Tarragona [Tarragona]
-
Reus, Tarragona [Tarragona], Espanja, 43204
- Hospital Universitari Sant Joan de Reus
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Espanja, 46017
- Hospital Universitario Doctor Peset
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Etelä -Korea, 13620
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Etelä -Korea, 02841
- Korea University Anam Hospital
-
Seoul, Seoul-teukbyeolsi [Seoul], Etelä -Korea, 08308
- Korea University Guro Hospital
-
-
Taegu-Kwangyǒkshi
-
Daegu, Taegu-Kwangyǒkshi, Etelä -Korea, 41404
- Kyungpook National University Chilgok Hospital
-
-
-
-
Central District
-
Kfar Saba, Central District, Israel, 4428164
- Meir Medical Center
-
Petah Tikva, Central District, Israel
- Rabin Medical Center
-
Ramat Gan, Central District, Israel, 5265601
- Sheba Medical Center
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 9112001
- Hadassah Medical Center
-
-
Southern District
-
Beersheba, Southern District, Israel, 8400000
- Soroka Medical Center
-
-
Tell Abīb
-
Tel Aviv, Tell Abīb, Israel, 6423906
- Sourasky Medical Center
-
-
-
-
-
Bari, Italia, 70124
- Instituto Tumori Giovanni Paolo II
-
Grosseto, Italia, 58100
- Ospedale Misericordia di Grosseto
-
Milan, Italia, 20132
- Ospedale San Raffaele
-
Viterbo, Italia, 01100
- ASL Viterbo Ospedale Belcolle
-
-
Catania
-
Misterbianco, Catania, Italia, 95045
- Humanitas Istituto Clinico Catanese
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italia, 47014
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
-
-
Friuli Venezia Giulia
-
Udine, Friuli Venezia Giulia, Italia, 33100
- P.O. "S. Maria della Misericordia" Azienda Sanitaria Universitaria Friuli Centrale
-
-
-
-
-
Thessaloniki, Kreikka, 546 45
- Euromedica General Clinic of Thessaloniki
-
-
Achaḯa
-
Pátrai, Achaḯa, Kreikka, 26504
- University Hospital of Patras
-
-
Attikí
-
Athens, Attikí, Kreikka, 115 28
- Alexandra Hospital
-
-
Irakleío
-
Heraklion, Irakleío, Kreikka, 711 10
- University General Hospital of Heraklion
-
-
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, Meksiko, 21200
- Centro de Investigacion en Artritis y Osteoporosis SC
-
Tijuana, Estado de Baja California, Meksiko, 22010
- COI Tijuana - Centro Oncológico Internacional
-
-
Jalisco
-
Guadalajara, Jalisco, Meksiko, 45647
- Centro Oncológico Internacional (COI)
-
-
Nuevo León
-
Monterrey, Nuevo León, Meksiko, 64060
- Centro Regiomontano de Investigación
-
-
San Luis Potosí
-
San Luis Potosí City, San Luis Potosí, Meksiko, 78209
- Oncologico Potosino, S.C.
-
-
-
-
Masovian Voivodeship
-
Otwock, Masovian Voivodeship, Puola, 05-400
- Europejskie Centrum Zdrowia - Oddzial Onkologii
-
-
Opole Voivodeship
-
Opole, Opole Voivodeship, Puola, 45-060
- Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
-
-
-
-
Aquitaine
-
Bordeaux, Aquitaine, Ranska, 33076
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
-
-
Finistère
-
Brest, Finistère, Ranska, 29609
- CHRU de Brest
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Ranska, 44277
- Hôpital privé du Confluent SAS
-
-
Vendée
-
La Roche-sur-Yon, Vendée, Ranska, 85000
- CHD Vendee
-
-
-
-
Stockholms
-
Stockholm, Stockholms, Ruotsi, 171 76
- Karolinska Universitetssjukhuset Solna
-
-
Örebro Län [se-18]
-
Örebro, Örebro Län [se-18], Ruotsi, 701 85
- Universitetssjukhuset Örebro
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Hospital
-
New Taipei City, Taiwan, 231
- Taipei Tzu Chi General Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 10449
- Mackay Memorial Hospital
-
Taoyuan, Taiwan, 333
- Chang Gung Medical Foundation-Linkou Branch
-
-
Tainan
-
Tainan, Tainan, Taiwan, 71004
- Chi Mei Medical Center
-
-
-
-
Capital Region
-
Copenhagen, Capital Region, Tanska, 2730
- Herlev and Gentofte Hospital
-
-
Central Jutland
-
Herning, Central Jutland, Tanska, 7400
- Regionshospitalet Gødstrup
-
-
-
-
-
Adana, Turkki (Türkiye), 01370
- Adana City Hospital
-
Ankara, Turkki (Türkiye), 06520
- Memorial Ankara Hastanesi
-
Ankara, Turkki (Türkiye), 06010
- Ankara Gülhane Eitim ve Aratrma Hastanesi
-
Diyarbakır, Turkki (Türkiye), 21200
- Dicle Üniversitesi
-
Edirne, Turkki (Türkiye), 22030
- Trakya University
-
Istanbul, Turkki (Türkiye), 34722
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
-
Malatya, Turkki (Türkiye), 44280
- İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi
-
-
Konya
-
Meram, Konya, Turkki (Türkiye), 42080
- Necmettin Erbakan Meram Medical Fac.
-
-
İzmir
-
Cordaleo, İzmir, Turkki (Türkiye), 009035575
- Izmir Medical Park Hospital
-
-
-
-
-
Hradec Králové, Tšekki, 500 05
- Fakultni nemocnice Hradec Kralove
-
-
Pardubice Region
-
Pardubice, Pardubice Region, Tšekki, 53203
- Multiscan
-
-
-
-
-
Budapest, Unkari, 1122
- Országos Onkológiai Intézet
-
Budapest, Unkari, 1062
- Magyar Honvedseg Egeszsegugyi Kozpont
-
-
Bács-Kiskun county
-
Kecskemét, Bács-Kiskun county, Unkari, 6000
- Bacs-Kiskun Megyei Korhaz
-
-
Győr-Moson-Sopron
-
Győr, Győr-Moson-Sopron, Unkari, 9024
- Petz Aladar Egyetemi Oktato Korhaz
-
-
-
-
Arizona
-
Phoenix, Arizona, Yhdysvallat, 85004
- St. Joseph's Hospital and Medical Center
-
-
Arkansas
-
Springdale, Arkansas, Yhdysvallat, 72762
- Highlands Oncology Group
-
-
California
-
Fullerton, California, Yhdysvallat, 92835
- Providence Medical Foundation
-
Los Alamitos, California, Yhdysvallat, 90720
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, Yhdysvallat, 90033
- Keck School of Medicine of USC
-
Los Angeles, California, Yhdysvallat, 90024
- TRIO-US (Translational Research in Oncology-US)
-
Santa Monica, California, Yhdysvallat, 90404
- UCLA Hematology/Oncology - Parkside
-
Sylmar, California, Yhdysvallat, 91342
- Olive View-UCLA Medical Center
-
Torrance, California, Yhdysvallat, 90505
- Torrance Memorial Physician Network / Cancer Care
-
Whittier, California, Yhdysvallat, 90602
- PIH Health Hematology Medical Oncology
-
-
Colorado
-
Denver, Colorado, Yhdysvallat, 80220
- Rocky Mountain Cancer Center - Hale Parkway
-
-
Florida
-
Fort Myers, Florida, Yhdysvallat, 33901-8101
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
Hollywood, Florida, Yhdysvallat, 33024
- Millennium Oncology Research Clinic
-
Miami, Florida, Yhdysvallat, 33136
- University of Miami Hospital and Clinics, Sylvester Cancer Center
-
Pensacola, Florida, Yhdysvallat, 32503
- Woodlands Medical Specialists, PA
-
Sarasota, Florida, Yhdysvallat, 34232
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
West Palm Beach, Florida, Yhdysvallat, 33401
- Florida Cancer Specialists EAST/Sarah Cannon Research Institute/SCRI
-
-
Georgia
-
Atlanta, Georgia, Yhdysvallat, 30322
- Winship Cancer Institute, Emory University
-
Gainesville, Georgia, Yhdysvallat, 30501
- Northeast Georgia Medical Center
-
Macon, Georgia, Yhdysvallat, 31201
- Central Georgia Cancer Care
-
-
Hawaii
-
Honolulu, Hawaii, Yhdysvallat, 96826
- Kapiolani Medical Center for Women and Children
-
-
Illinois
-
Harvey, Illinois, Yhdysvallat, 60426
- Ingalls Memorial Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, Yhdysvallat, 70809
- Hematology Oncology Clinic- Baton Rouge/Sarah Cannon Research Institute/SCRI
-
Lake Charles, Louisiana, Yhdysvallat, 70601
- Clinical Trials of SWLA
-
-
Maine
-
Lewiston, Maine, Yhdysvallat, 04240
- Central Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Yhdysvallat, 21237
- Mfsmc-Hjwci
-
Clinton, Maryland, Yhdysvallat, 20735
- Maryland Oncology Hematology, P.A. - Clinton
-
-
Massachusetts
-
Boston, Massachusetts, Yhdysvallat, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Yhdysvallat, 02215
- Dana Farber Cancer Institute
-
Danvers, Massachusetts, Yhdysvallat, 01923
- MGH Northshore Cancer Center
-
Fairhaven, Massachusetts, Yhdysvallat, 02719
- Southcoast Centers for Cancer Care
-
Foxborough, Massachusetts, Yhdysvallat, 02035
- Dana-Farber Cancer Institute - Foxborough
-
Methuen, Massachusetts, Yhdysvallat, 01844
- Dana Farber Cancer Center Merrimack Valley
-
Milford, Massachusetts, Yhdysvallat, 01757
- Dana Farber Cancer Institute
-
Newton, Massachusetts, Yhdysvallat, 02462
- Mass General Cancer Center
-
South Weymouth, Massachusetts, Yhdysvallat, 02190
- Dana Farber Cancer Institute
-
Worcester, Massachusetts, Yhdysvallat, 01606
- Reliant Medical Group
-
-
Montana
-
Billings, Montana, Yhdysvallat, 59102
- St. Vincent Frontier Cancer Center
-
-
New Hampshire
-
Londonderry, New Hampshire, Yhdysvallat, 03053
- Dana Farber Cancer Center Londonderry
-
-
New Mexico
-
Albuquerque, New Mexico, Yhdysvallat, 87106
- University of New Mexico Comprehensive Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, Yhdysvallat, 02906
- Lifespan Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, Yhdysvallat, 37404
- Tennessee Oncology-Chattanooga /Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, Yhdysvallat, 37203
- Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, Yhdysvallat, 37203
- Tennessee Oncology-Nashville/Sarah Cannon Research Institute/SCRI
-
-
Texas
-
Bedford, Texas, Yhdysvallat, 76022
- Texas Oncology - Bedford
-
Denton, Texas, Yhdysvallat, 76201
- Texas Oncology - Denton
-
El Paso, Texas, Yhdysvallat, 79902
- Texas Oncology, P.A.
-
Houston, Texas, Yhdysvallat, 77030-4009
- University of Texas MD Anderson Cancer Center
-
McKinney, Texas, Yhdysvallat, 75071
- Texas Oncology - McKinney
-
McKinney, Texas, Yhdysvallat, 75071
- Woodlands Medical Specialists, PA
-
Mesquite, Texas, Yhdysvallat, 75150
- Woodlands Medical Specialists, PA
-
Plano, Texas, Yhdysvallat, 75093
- Texas Oncology-Plano West
-
Plano, Texas, Yhdysvallat, 75075-7787
- Texas Oncology - Plano East
-
San Antonio, Texas, Yhdysvallat, 78229
- Mays Cancer Center
-
The Woodlands, Texas, Yhdysvallat, 77380
- US Oncology
-
Tyler, Texas, Yhdysvallat, 75702
- Texas Oncology - Tyler Cancer Center
-
-
Utah
-
Murray, Utah, Yhdysvallat, 84107
- Intermountain Medical Center
-
St. George, Utah, Yhdysvallat, 84790
- Intermountain Healthcare - St. George
-
-
Vermont
-
Burlington, Vermont, Yhdysvallat, 05401
- The University of Vermont Medical Center Inc.
-
-
Virginia
-
Winchester, Virginia, Yhdysvallat, 22601
- Shenandoah Oncology, P.C.
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
-
Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer
-
Have radiologic evidence of disease progression or recurrence either
- On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
- On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
-
Must be deemed appropriate for treatment with ET
-
If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression
-
Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)
-
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)
-
Have adequate renal, hematologic, and hepatic organ function
-
Must be able to swallow capsules/tablets
Exclusion Criteria:
- Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
- Have symptomatic or untreated central nervous system metastasis
- Have received any systemic therapy between disease recurrence/progression and study screening
- Have received more than 1 line of therapy for advanced or metastatic disease.
- Have received prior chemotherapy for metastatic breast cancer (MBC)
- Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Arm A: Abemaciclib plus Fulvestrant
Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered orally. Administered IM. |
|
Active Comparator: Arm B: Placebo plus Fulvestrant
Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered IM. Administered orally. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Progression-Free Survival (PFS)
Aikaikkuna: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Aikaikkuna: Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
|
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
Aikaikkuna: Randomization until measured progressive disease (Up to 22 Months)
|
ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. |
Randomization until measured progressive disease (Up to 22 Months)
|
Yhteistyökumppanit ja tutkijat
Sponsori
Tutkijat
- Opintojohtaja: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. Int J Mol Sci. 2025 Mar 14;26(6):2643. doi: 10.3390/ijms26062643.
- Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Munoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18.
- Kalinsky K, Wander SA, Hamilton E, Graff SL, Jeselsohn R, Park KH, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Ravenberg E, Amdur S, Litchfield LM, Bianchini G. Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. Ann Oncol. 2026 Oct 24:S0923-7534(26)08075-0. doi: 10.1016/j.annonc.2026.10.1283. Online ahead of print.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
- Patologiset prosessit
- Neoplasmat sivustoittain
- Neoplasmat
- Neoplastiset prosessit
- Ihosairaudet
- Rintojen sairaudet
- Patologiset tilat, merkit ja oireet
- Iho- ja sidekudostaudit
- Rintojen kasvaimet
- Neoplasman metastaasit
- Hormonit
- Hormonit, hormonikorvikkeet ja hormoniantagonistit
- Polisykliset yhdisteet
- Steroidit
- Sulatettu rengasyhdisteet
- Estradioli
- Esreenit
- Estaanit
- Estradioli -yhdistäjät
- Gonadal -steroidihormonit
- Gonadal -hormonit
- Fulvestrantti
- abemaciclib
Muut tutkimustunnusnumerot
- 18238
- I3Y-MC-JPEF (Muu tunniste: Eli Lilly and Company)
- 2021-002301-10 (EudraCT-numero)
- 2023-506771-10-00 (Muu tunniste: EU Trial Number)
- 2023 (Yhdysvaltain NIH-apuraha/sopimus)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-jaon aikakehys
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD-jaon käyttöoikeuskriteerit
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
- MAHLA
- CSR
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .